These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 25079928)
1. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC; BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928 [TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW Ophthalmology; 2014 Apr; 121(4):936-45. PubMed ID: 24405740 [TBL] [Abstract][Full Text] [Related]
4. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. ; Chakravarthy U; Harding SP; Rogers CA; Downes SM; Lotery AJ; Wordsworth S; Reeves BC Ophthalmology; 2012 Jul; 119(7):1399-411. PubMed ID: 22578446 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). Stein JD; Newman-Casey PA; Mrinalini T; Lee PP; Hutton DW Trans Am Ophthalmol Soc; 2013 Sep; 111():56-69. PubMed ID: 24167325 [TBL] [Abstract][Full Text] [Related]
6. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Elshout M; van der Reis MI; Webers CA; Schouten JS Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1911-20. PubMed ID: 24777708 [TBL] [Abstract][Full Text] [Related]
7. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration. Brown GC; Brown MM; Rapuano S; Boyer D Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050 [TBL] [Abstract][Full Text] [Related]
8. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Chakravarthy U; Harding SP; Rogers CA; Downes SM; Lotery AJ; Culliford LA; Reeves BC; Lancet; 2013 Oct; 382(9900):1258-67. PubMed ID: 23870813 [TBL] [Abstract][Full Text] [Related]
9. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration]. Li H; Li X; Xie F Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975 [TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model. Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318 [TBL] [Abstract][Full Text] [Related]
11. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity. Butt T; Patel PJ; Tufail A; Rubin GS Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes. Butt T; Lee A; Lee C; Tufail A; BMJ Open; 2015 May; 5(5):e006535. PubMed ID: 25943370 [TBL] [Abstract][Full Text] [Related]
15. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392 [No Abstract] [Full Text] [Related]
16. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Stein JD; Newman-Casey PA; Kim DD; Nwanyanwu KH; Johnson MW; Hutton DW Ophthalmology; 2013 Sep; 120(9):1835-42. PubMed ID: 23642372 [TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018 [TBL] [Abstract][Full Text] [Related]
18. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema. Brown GC; Brown MM; Turpcu A; Rajput Y Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective. Nunes RP; Hirai FE; Rodrigues EB; Farah ME Arq Bras Oftalmol; 2020; 83(1):48-54. PubMed ID: 32130306 [TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. Brown GC; Brown MM; Monigle MC Ophthalmol Retina; 2024 May; 8(5):431-446. PubMed ID: 37981235 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]